Biophytis SA (BPTS): Price and Financial Metrics
BPTS Price/Volume Stats
Current price | $8.22 | 52-week high | $168.80 |
Prev. close | $9.70 | 52-week low | $8.05 |
Day low | $8.05 | Volume | 18,500 |
Day high | $8.96 | Avg. volume | 7,291 |
50-day MA | $16.22 | Dividend yield | N/A |
200-day MA | $35.36 | Market Cap | 2.89M |
BPTS Stock Price Chart Interactive Chart >
Biophytis SA (BPTS) Company Bio
Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Its second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry ager elated macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101). The company was founded in 2006 and is headquartered in Paris, France.
BPTS Price Returns
1-mo | N/A |
3-mo | N/A |
6-mo | N/A |
1-year | -72.91% |
3-year | -99.65% |
5-year | N/A |
YTD | -69.36% |
2023 | -83.02% |
2022 | -92.60% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...